Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Preclinical Development: Overview01:28

Preclinical Development: Overview

5.7K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
5.7K
Clinical Trials: Overview01:11

Clinical Trials: Overview

4.5K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.5K
Drug Discovery: Overview01:26

Drug Discovery: Overview

10.9K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
10.9K
Drug Administration and Therapy Phases: Overview01:26

Drug Administration and Therapy Phases: Overview

1.1K
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
1.1K
In Vitro Drug Release Testing: Overview, Development and Validation01:10

In Vitro Drug Release Testing: Overview, Development and Validation

279
In vitro dissolution and drug release tests assess how quickly and how much of a drug is released from its dosage form into an aqueous medium under standardized laboratory conditions. These tests are essential tools in pharmaceutical development and quality assurance, offering insight into the drug's performance before clinical use.During formulation development, dissolution testing identifies incomplete or inconsistent drug release issues. It also supports decisions on selecting the optimal...
279
Drug Regulation01:25

Drug Regulation

2.7K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
2.7K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

In-depth characterization of the Ca<sub>V</sub>2.2-knockout mouse line.

Scientific reports·2026
Same author

Catatonia associated with mosaic 18q deletion syndrome: a case report.

BMC psychiatry·2026
Same author

Minimal <i>N</i>-methylated and stapled peptide inhibitors of the autophagy protein GABARAP.

RSC chemical biology·2026
Same author

Clonal Hematopoiesis of Indeterminate Potential as an Emerging Interdisciplinary Risk Factor in Alzheimer's Disease: Current Evidence and Future Directions.

Biomedicines·2026
Same author

Elucidation of the influence of the Ca<sub>V</sub>2.2 calcium channel on ALS disease progression in the SOD1*G93A mouse model.

Neurobiology of disease·2026
Same author

Inhibition of Chikungunya virus nsP2 protease in vitro by scorpion venom peptide pantinin-1.

PloS one·2026

相关实验视频

Updated: Jan 7, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

10.1K

药物开发 药物开发

Dieter Willbold1,2,3, Janine Kutzsche4, Nicoleta Carmen Cosma5

  • 1Priavoid, Jülich, Germany.

Alzheimer's & dementia : the journal of the Alzheimer's Association
|December 25, 2025
PubMed
概括
此摘要是机器生成的。

实验性药物PRI-002,向粉样β oligomers,在患有早期阿尔茨海默病的患者中显示出良好的耐受性. 虽然没有观察到生物标志物变化,但与安慰剂相比,在PRI-002组中发现了显著的记忆改善.

更多相关视频

In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing
08:04

In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing

Published on: May 11, 2021

3.3K
Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells
05:45

Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells

Published on: October 10, 2025

451

相关实验视频

Last Updated: Jan 7, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

10.1K
In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing
08:04

In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing

Published on: May 11, 2021

3.3K
Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells
05:45

Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells

Published on: October 10, 2025

451

科学领域:

  • 神经科学是一个神经科学.
  • 药理学 药理学是指药理学的学科.
  • 生物化学 生物化学

背景情况:

  • 自复制的粉样β (Aβ) 寡合体与阿尔茨海默病 (AD) 病原发生有关,导致突触毒性和认知衰退.
  • D-enantiomericPRI-002旨在将有毒的Aβ寡合体分解为单体,作为潜在的治疗剂.
  • 在临床前模型中,PRI-002已经证明了目标参与和有效性,可以逆转认知缺陷,并且在健康的志愿者中是安全的.

研究的目的:

  • 评估PRI-002在患有轻度认知障碍 (MCI) 和因AD而导致轻度痴呆症的患者的安全性和耐受性.
  • 探索PRI-002在这个患者群体中的药理动力学和潜在疗效.

主要方法:

  • 一项随机的,安慰剂控制的,双盲的1b期研究与20名因AD而被诊断为MCI到轻度痴呆症的患者进行.
  • 患者每天接受300毫克PRI-002或安慰剂,持续28天,在56日进行后续评估.
  • 安全性评估包括不良事件,心电图,EEG,MRI和脑脊液 (CSF) 生物标志物;通过认知测试评估有效性.

主要成果:

  • PRI-002的耐受性很好,没有严重的不良事件 (SAE) 或ECG,EEG或MRI的显著变化.
  • 在CSF生物标志物中没有发现显著的变化,包括p-tau,t-tau,Aβ 1-40,Aβ 1-42和Aβ寡合体.
  • 与安慰剂组相比,接受PRI-002治疗的患者在短期记忆方面表现出显著的改善 (CERAD词汇列表,第56天与基线相比,p<0.01).

结论:

  • 在患有MCI和因AD而引起的轻度痴呆症的患者中,PRI-002是安全的,并且耐受性良好.
  • 经过28天的治疗,测量的生物标志物没有显著变化.
  • 在PRI-002组中显著的记忆改善表明了潜在的治疗疗效,需要在第二阶段研究中进一步调查.